SPYRE THERAPEUTICS, INC. Shareholders' Equity
SPYRE THERAPEUTICS, INC. (SYRE) had Shareholders' Equity of $1.10 billion as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-04
- 2026-06-30: Stockholders' Equity Attributable to Parent $1.10B.
- 2026-03-31: Stockholders' Equity Attributable to Parent $670.81M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $715.24M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $455.10M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $1.10B 10-Q · filed 2026-08-04 |
| 2026-03-31 | $670.81M 10-Q · filed 2026-08-04 |
| 2025-12-31 | $715.24M 10-Q · filed 2026-08-04 |
| 2025-09-30 | $455.10M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $455.77M 10-Q · filed 2026-08-04 |
| 2025-03-31 | $482.61M 10-Q · filed 2026-08-04 |
| 2024-12-31 | $517.80M 10-Q · filed 2026-08-04 |
| 2024-09-30 | $327.39M 10-Q · filed 2025-11-04 |
| 2024-06-30 | $374.38M 10-Q · filed 2025-11-04 |
| 2024-03-31 | $152.27M 10-Q · filed 2025-11-04 |
| 2023-12-31 | $184.02M 10-K · filed 2026-02-19 |
| 2023-09-30 | -$245.40M 10-Q/A · filed 2024-11-18 |
| 2023-06-30 | -$207.37M 10-Q/A · filed 2024-11-18 |
| 2023-03-31 | $33.65M 10-Q/A · filed 2024-11-18 |
| 2022-12-31 | $50.30M 10-K · filed 2026-02-19 |
| 2022-09-30 | $67.56M 10-Q · filed 2023-11-09 |
| 2022-06-30 | $84.16M 10-Q · filed 2023-11-09 |
| 2022-03-31 | $61.66M 10-Q · filed 2023-11-09 |
| 2021-12-31 | $83.94M 10-K · filed 2025-02-27 |
| 2021-09-30 | $102.08M 10-Q · filed 2022-11-03 |
| 2021-06-30 | $119.02M 10-Q · filed 2022-11-03 |
| 2021-03-31 | $123.75M 10-Q · filed 2022-11-03 |
| 2020-12-31 | $139.83M 10-K/A · filed 2024-11-18 |
| 2020-09-30 | $136.27M 10-Q · filed 2021-11-04 |
| 2020-06-30 | $152.26M 10-Q · filed 2021-11-04 |
| 2020-03-31 | $42.80M 10-Q · filed 2021-11-04 |
| 2019-12-31 | $60.08M 10-K · filed 2023-03-02 |
| 2019-09-30 | $79.80M 10-Q · filed 2020-11-05 |
| 2019-06-30 | $99.61M 10-Q · filed 2020-11-05 |
| 2019-03-31 | $116.29M 10-Q · filed 2020-11-05 |
| 2018-12-31 | $67.43M 10-K · filed 2022-03-08 |
| 2018-09-30 | $63.68M 10-Q · filed 2019-11-06 |
| 2018-06-30 | $73.45M 10-Q · filed 2019-11-06 |
| 2018-03-31 | $43.92M 10-Q · filed 2019-11-06 |
| 2017-12-31 | $50.34M 10-K · filed 2021-03-18 |
| 2017-09-30 | $55.51M 10-Q · filed 2017-11-07 |
| 2017-06-30 | $62.60M 10-Q · filed 2017-08-09 |
| 2017-03-31 | $57.18M 10-Q · filed 2017-05-09 |
| 2016-12-31 | $62.97M 10-K · filed 2020-02-24 |
| 2016-09-30 | $68.20M 10-Q · filed 2016-11-09 |
| 2016-06-30 | $73.92M 10-Q · filed 2016-08-09 |
| 2016-03-31 | -$26.61M 10-Q · filed 2016-05-19 |
| 2015-12-31 | -$22.21M 10-K · filed 2019-03-07 |
| 2014-12-31 | -$11.47M 10-K · filed 2018-03-13 |
| 2013-12-31 | -$1.27M 10-K · filed 2017-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |